Just found this article, don't think it has been posted...

Just found this article, don't think it has been posted before.

Taking the Long-Term view of China Healthcare

China has around 20 per cent of the world?s population and currently represents about 1.5 per cent of the global pharmaceutical market, but this imbalance is changing fast as China?s extraordinary economic growth continues.

Although not yet established in China, emerging and ambitious Australian publicly listed healthcare company, Stirling Products Limited, has China firmly in its sights for future expansion and growth.

Stirling Products see major opportunities for a number of their healthcare products, which include a significant drug candidate for obesity, its complex botanical immunomodulator for tuberculosis, HIV and hepatitis. The company also sees immediate potential for its key device products within this massive and rapidly developing market.

Stirling Products? remote vital signs monitoring units are currently the most advanced eHealth multi-user devices on the market. Their advantage, especially within the major population centres of China, is that the units can service hundreds of patients securely, without risk of compromising patient records or privacy and with all clinical records being encrypted with access to real-time or stored monitoring data only available to the patient or their authorised carer or medical practitioner.

The TeleMedCare devices are already used by over 20,000 patients in Australia and the UK, and can remotely and securely measure, graph or otherwise record:

weight
body temperature
blood pressure
blood oximetry
blood glucose
spirometry (lung function)
electrocardiogram ? ECG (heart function)
questionnaires
scheduling
health diary
Stirling Products also sees their High Density Aerosol (HDA) delivery platform as having significant potential for the future delivery of drugs to patients in China. This platform provides for the pulmonary delivery of drugs in their liquid form, which is accepted as an optimal drug delivery method that can provide for the better and safer delivery of drugs.

The major benefit of HDA drug administration is that it promises to provide the same efficacy as drugs taken orally, with far less active drug content.

Key features of HDA technology
Drug transportation velocity (delivery) is matched to the patient?s natural inhalation.
Delivers three times the aerosol concentration of conventional ultrasonic devices.
Provides a concentration level between that currently achieved with dry powder inhalers and conventional fan-driven nebulisers.
Delivers drugs with much faster absorption and much lower transportation losses.
Aerosol concentration during inhalation is adapted to natural patient breathing.
The active drug particle size is substantially sub-5 micron, providing for better and more rapid absorption.
Active drug is in unique disposable capsules, further protecting against competition.
Compared to oral administration, testing has shown substantially LESS active drug could be required to provide the same benefit therefore also potentially increasing safety and lessening side effects.
Can potentially be used for administration of most drugs.
For further information see
www.stirlingproducts.net

link:
http://www.australiachina.com.au/biotechnology/chinese-healthcare